FINWIRES · TerminalLIVE
FINWIRES

CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China

By

CSPC Pharmaceutical Group (HKG:1093) and AstraZeneca have agreed to establish a joint venture to build a new-generation biologics manufacturing facility in Shijiazhuang, China, as part of their strategic collaboration.

Under the agreement, CSPC will hold a 51% stake in the JV, while AstraZeneca will own the remaining 49%. The two companies will jointly manage the construction and operations of the facility.

The JV will initially focus on manufacturing and supplying agreed biologic drug substances for global markets, with potential to expand its product scope as capacity and demand grow. The agreement remains subject to customary closing conditions, including regulatory approvals.

Related Articles

Asia

India's Market Regulator Eyes Depository Receipt Framework for REITs, Public InvITs

India's market regulator has proposed allowing real estate investment trusts (REITs) and publicly listed infrastructure investment trusts (InvITs) to issue depository receipts, according to a consultation paper published on Tuesday.The Securities and Exchange Board of India (SEBI) is proposing an enabling framework for the issuance of depository receipts backed by units of REITs and publicly listed InvITs.The regulator said the instruments would allow foreign investors to trade the securities in foreign currency on permitted international exchanges.SEBI proposed amending the REIT and InvIT regulations to permit such issuances and plans to introduce a detailed framework through a separate circular.Public comments on the consultation paper are invited until Aug. 25.

^BSENifty 50
Asia

Sharetronic Data Technology Adds 150 Million Yuan in Related Party Deals

Sharetronic Data Technology (SHE:300857) said its board approved 150 million yuan in new 2026 related-party transactions with Cheng Uei Precision for Internet of Things smart terminal product sales.This raised the annual total to 350 million yuan, according to a Wednesday filing with the Shenzhen bourse.Shares of the wireless telecommunication equipment manufacturer rose 6% in recent trade.

SHE:300857
Asia

Helens International Forecasts Lower Net Profit in H1

Helens International (SGX:HLS, HKG:9869) expects to book a net profit of up to 16 million yuan, compared with an adjusted net profit of 50.3 million yuan a year earlier.Meanwhile, the company expects a revenue of up to 260 million yuan in the first half of the year, compared to 291.2 million yuan a year earlier, according to a Tuesday filing with the Singapore Exchange.The decrease in revenue is mainly due to a decline in the number of self-operated bars during the period.

HKG:9869SGX:HLS